Capital World Investors
SYRE icon

Capital World Investors’s Spyre Therapeutics SYRE Stock Holding History

Capital World Investors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206M Buy
2,315,553
+1,648,989
+247% +$120M 0.02% 317
2026
Q1 		$33.6M Buy
666,564
+466,392
+233% +$17.6M ﹤0.01% 499
2025
Q4 		$6.56M Hold
200,172
– – ﹤0.01% 516
2025
Q3 		$3.35M Sell
200,172
-150,602
-43% -$2.46M ﹤0.01% 526
2025
Q2 		$5.25M Hold
350,774
– – ﹤0.01% 515
2025
Q1 		$5.66M Sell
350,774
-27,799
-7% -$578K ﹤0.01% 500
2024
Q4 		$8.81M Buy
+378,573
New +$11.1M ﹤0.01% 485

Other funds holding SYRE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Capital World Investors's SYRE Position: Q2 2026 in Review

Capital World Investors increased its Spyre Therapeutics (SYRE) stake by 247% in Q2 2026, buying an estimated $120M and bringing the position to 2,315,553 shares worth $206M. The position accounts for 0.02% of the portfolio, ranked #317.

Capital World Investors first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 148 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Capital World Investors held 2,315,553 shares of Spyre Therapeutics worth $206M as of Q2 2026.
  • Capital World Investors bought 1,648,989 Spyre Therapeutics shares in Q2 2026, an estimated $120M.
  • Spyre Therapeutics made up 0.02% of Capital World Investors's portfolio in Q2 2026, its #317 holding.
  • Capital World Investors first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 148 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.